

Pain Management Patient Monitoring



www.aruplab.com


ARUP LABORATORIES 500 Chipeta Way Salt Lake City, UT 84108-1221 Phone: (800) 522-2787 Fax: (801) 583-2712

keyword: drug-panel

A nonprofit enterprise of the University of Utah and its Department of Pathology

> © 2018 ARUP Laboratories BD-CS-016, Rev 5, February 2018





ARUP's unique approach to pain management patient monitoring offers physicians multiple choices.

Pain Management Drug Panel by Mass Spectrometry and Enzyme Immunoassay, Urine

test code	2007479
method	Qualitative liquid chromatography/mass spectrometry/enzyme immunoassay/ quantitative spectrophotometry
turnaround time	1–3 days
CPT codes	80307

Pain Management Drug Screen with Interpretation by Mass Spectrometry and Enzyme Immunoassay. Urine

test code	2009288
with interpretation	Patient medication information must be provided to receive interpretation.
	To see a sample report, please visit: www.aruplab.com/testing/enhanced- reports
turnaround time	1-4 days
CPT codes	80307

Pain Management Extended Drug Panel by Immunoassay with Reflex to LC/MS/MS **Quantitative Confirmation, Urine**

test code	2012312
method	Qualitative Enzyme Multiplied Immunoassay and LC/MS/MS
turnaround time	1-8 days
CPT codes	80307 if positive add appropriate CPT: 80324; 80359; 80345; 80346; 80348; 80369; 80353; 80321; 80354; 80362; 80358; 80349; 80361; 80365; 83992; 80367; 80368; 80372; 80373 (Alt code: if positive, add appropriate CPT code(s): G0480)

ARUP Offers Traditional Quantitative Results with Screen and Reflex Panel

In select situations, a quantitative result can assist physicians in the monitoring or treatment of their patients. As a complement to our qualitative mass spectrometry panels, ARUP offers physicians an immunoassay with auto reflex to LC/MS/MS quantitative results.

The extended Pain Management Panel, Screen with Reflex to Quantitation (2012312) was designed to meet the granularity requirements of monitoring pain management patients while being mindful of the cost to both the patient and the health system.

If a confirmation is needed, ARUP will automatically reflex to LC/MS/MS methodology on any of the drug classes. Our three panels complement pain management testing requirements while helping reduce patient out-of-pocket expenses.

Resolving Unanswered Questions

Immunoassay screens and point-of-care cups may report opiates as a class but not as individual drugs, leaving certain questions unanswered: What was positive? What was tested? Benzodiazepines, for example, tend to be a source of false negatives, as they are poorly sensitive to the metabolite of clonazepam. ARUP's qualitative mass spectrometry panels use advanced technologies, reducing unexpected or ambiguous results and the need for costly confirmation testing.

Features and Benefits

- Comprehensive, highly-specific results for over 40 drugs and metabolites where immunoassays are not adequate
- · Significant decrease in time and testing expenses
- Reduced need for most confirmation testing
- · Available with interpretation
- · Single-drug confirmations also available
- Performed 7 days per week

Drugs Reported in the Qualitative Mass Spectrometry Urine Drug Panels (test codes 2007479, 2009288)

OPIATES/OPIOIDS

6-acetylmorphine (heroin metabolite) **Buprenorphine** Buprenorphine-glucuronide Norbuprenorphine Codeine Fentanyl Norfentanyl Hydrocodone Dihydrocodeine Norhydrocodone Hydromorphone Meperidine metabolite Methadone* Morphine Oxvcodone Noroxycodone Oxymorphone Noroxymorphone Propoxyphene* Tapentadol Tapentadol-o-sulfate Tramadol*

AMPHETAMINES

Amphetamine Methamphetamine MDMA-Ecstasy

MDA MDFA-Fve Methylphenidate Phentermine

BENZODIAZEPINES

Alprazolam -Alpha-OH-alprazolam Clonazepam -7-aminoclonazepam Diazepam Nordiazepam Oxazepam Temazepam Lorazepam Midazolam Zolpidem

OTHER*

Carisoprodol/meprobamate Cocaine metabolite Marijuana metabolite PCP Ethyl glucuronide Creatinine *Analyzed by immunoassay or spectrophotometry

Barbiturates